Peterson Financial Group Inc. reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 74.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,585 shares of the company’s stock after selling 10,562 shares during the quarter. Johnson & Johnson accounts for 0.9% of Peterson Financial Group Inc.’s portfolio, making the stock its 24th largest position. Peterson Financial Group Inc.’s holdings in Johnson & Johnson were worth $633,000 as of its most recent SEC filing.
Several other institutional investors also recently bought and sold shares of JNJ. Veracity Capital LLC raised its holdings in Johnson & Johnson by 1.2% in the 4th quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock worth $888,000 after purchasing an additional 59 shares during the period. Sandy Cove Advisors LLC raised its holdings in Johnson & Johnson by 1.6% during the third quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company’s stock valued at $605,000 after acquiring an additional 60 shares during the period. LCM Capital Management Inc raised its holdings in Johnson & Johnson by 0.7% during the fourth quarter. LCM Capital Management Inc now owns 9,437 shares of the company’s stock valued at $1,667,000 after acquiring an additional 61 shares during the period. Arbor Investment Advisors LLC raised its holdings in Johnson & Johnson by 2.3% during the fourth quarter. Arbor Investment Advisors LLC now owns 2,697 shares of the company’s stock valued at $476,000 after acquiring an additional 61 shares during the period. Finally, Mason & Associates Inc increased its holdings in shares of Johnson & Johnson by 4.9% in the third quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock worth $215,000 after purchasing an additional 62 shares during the last quarter. 67.94% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson Stock Down 0.1 %
JNJ opened at $163.60 on Tuesday. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $183.35. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35. The company has a 50-day moving average price of $157.86 and a 200 day moving average price of $167.04. The company has a market cap of $426.06 billion, a PE ratio of 34.23, a price-to-earnings-growth ratio of 2.78 and a beta of 0.53.
Johnson & Johnson Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be issued a dividend of $1.19 per share. The ex-dividend date is Monday, May 22nd. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.91%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio (DPR) is currently 94.56%.
Insider Transactions at Johnson & Johnson
In related news, insider James D. Swanson sold 1,062 shares of the stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the transaction, the insider now owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.20% of the company’s stock.
Analysts Set New Price Targets
Several research firms recently commented on JNJ. Piper Sandler dropped their price target on Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. Raymond James lowered their price target on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a report on Wednesday, April 19th. StockNews.com initiated coverage on Johnson & Johnson in a report on Thursday, March 16th. They issued a “strong-buy” rating for the company. Guggenheim initiated coverage on Johnson & Johnson in a report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price target for the company. Finally, Morgan Stanley boosted their price target on Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a report on Wednesday, April 19th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $173.00.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Stories
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Insiders Drive Volatility For Keurig Dr Pepper
- After a 40% Drop, Analysts Remain Bullish on Impinj
- Visa Charges Higher After Better-Than-Expected Q2 Report
- onsemi Puts A Bottom in Chip Stocks, Heads For New Highs
- Can Teladoc Stock Be Resuscitated?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
